Prevacid NapraPAC Articles
Takeda: half-year results
4 December 1995
US FDA Approving Fewer NMEs, But Faster, In 1995
11 September 1995
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
EU: Pluses And Minuses Of Pharmacoeconomics
17 July 1995
FDA Clears New Labelling For Prilosec
20 March 1995
UK Code Authority May Become Self-Supporting
20 March 1995
Takeda Abbott Gains FDA Status
27 February 1995
Glaxo Interim Profits Up 10% On 2% Sales Rise
13 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Takeda Expands In The UK
16 January 1995
Losec For GERD Maintenance In USA
12 December 1994
Abbott's AIDS Drug In Phase I/II Studies
24 October 1994
1-Hour Treatment For H Pylori?
17 October 1994
Eradication Therapy For Helicobacter Pylori
10 October 1994
European Stock Comment
12 September 1994
France Cuts Drug Prices, Bans Promo Campaigns
5 September 1994
Takeda Advancing Despite Challenging Environment
5 September 1994
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
Leuplin Gains Two Additional Indications
1 August 1994
ASTRA AND TAKEDA SETTLEMENT
30 May 1994
LANSOPRAZOLE ADVERSE REACTIONS
30 May 1994
IMPROVED 1st QTR FOR CYANAMID
25 April 1994
ZOTON OFFERS BENEFITS OVER H2S & OMEPRAZOLE
18 April 1994
NDA FILED FOR PREVACID IN USA
28 February 1994
EISAI FILES NDA FOR PROTON PUMP DRUG
28 February 1994
TAKEDA IN GERMAN POLICE ENQUIRY
6 December 1993
ASTRA LAUNCHES 40mg LOSEC TABLET
11 October 1993
TOKYO TANABE TO CODEVELOP TU-199
11 October 1993
ABBOTT'S HYTRIN GETS BPH APPROVAL IN USA
11 October 1993
ASTRA DEFENDS LOSEC PATENT RIGHTS
2 August 1993
ABBOTT ACHIEVES RECORD SALES
19 April 1993
GLOBAL SALES OF H2 BLOCKERS TO DECLINE?
1 March 1993
PRETAX AND EPS SOAR AT ASTRA IN 1992
1 March 1993
NEW CHEMICAL ENTITIES LAUNCHED IN 1992
1 February 1993
TAKEDA LAUNCH
21 December 1992
LANSOPRAZOLE READY FOR LAUNCH
14 December 1992
H PYLORI TREATMENT: A ROLE FOR OMEPRAZOLE?
25 May 1992
FIRST LAUNCH OF LANSOPRAZOLE
20 January 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
